Main characteristics of patients with DLBCL according to the occurrence of CNS event
| . | All patients (n = 2203) . | Patients without CNS event (n = 2163) . | Patients with CNS event (n = 40) . | P value∗ . |
|---|---|---|---|---|
| Male, n (%) | 1292 (59) | 1266 (59) | 26 (65) | .410 |
| Female, n (%) | 911 (41) | 897 (41) | 14 (35) | |
| Age, median (range), y | 47 (18-60) | 47 (18-60) | 51 (19-60) | .370 |
| LDH > upper normal value, n (%) | 1102 (50) | 1070 (49) | 32 (80) | <.001 |
| ECOG >1, n (%) | 193 (9) | 183 (8) | 10 (25) | .002 |
| Stage III/IV, n (%) | 1031 (47) | 1003 (46) | 28 (70) | .003 |
| aaIPI, n (%) | ||||
| 0 | 652 (30) | 651 (30) | 1 (2) | <.001 |
| 1 | 924 (42) | 906 (42) | 18 (45) | |
| 2 | 479 (22) | 468 (22) | 11 (28) | |
| 3 | 148 (7) | 138 (6) | 10 (25) | |
| Extralymphatic involvement, n (%) | 1210 (55) | 1183 (55) | 27 (68) | .107 |
| Extralymphatic involvement >1, n (%) | 509 (23) | 496 (23) | 13 (32) | .155 |
| Bulky disease† (>10 cm), n (%) | 462 (21) | 448 (21) | 14 (35) | .029 |
| B symptoms, n (%)† | 654 (30) | 635 (29) | 19 (49) | .009 |
| BM involvement, n (%) | 142 (6) | 135 (6) | 7 (18) | .012 |
| Kidney involvement at staging, n (%) | 56 (3) | 53 (2) | 3 (8) | .079 |
| Adrenal gland involvement at staging, n (%) | 33 (1) | 31 (1) | 2 (5) | .119 |
| Kidney and/or adrenal gland involvement at staging, n (%) | 81 (4) | 77 (4) | 4 (10) | .057 |
| CNS-IPI, n (%) | ||||
| 0 | 640 (29) | 639 (30) | 1 (2) | <.001 |
| 1 | 759 (34) | 744 (34) | 15 (38) | |
| 2 | 414 (19) | 403 (19) | 11 (28) | |
| 3 | 251 (11) | 245 (11) | 6 (15) | |
| 4 | 119 (5) | 116 (5) | 3 (8) | |
| 5 | 20 (1) | 16 (1) | 4 (10) | |
| CNS-IPI groups, n (%) | .002 | |||
| 0-1, low risk | 1399 (64) | 1383 (64) | 16 (40) | |
| 2-3, intermediate risk | 665 (30) | 648 (30) | 17 (42) | |
| 4-5, high risk | 139 (6) | 132 (6) | 7 (18) | |
| MTX prophylaxis (at least 1 course), n (%) | — | |||
| MTX IT† | 780 (38) | 766 (38) | 14 (40) | |
| HD MTX IV | 344 (16) | 342 (16) | 2 (5) | |
| CNS event, n (%) | — | — | ||
| At first progression/relapse (within the first 3 y) | 33 (1.5) (27) | 33 (82) (27) | ||
| After first progression/relapse (within the first 3 y) | 7 (0.3) (4) | 7 (18) (4) |
| . | All patients (n = 2203) . | Patients without CNS event (n = 2163) . | Patients with CNS event (n = 40) . | P value∗ . |
|---|---|---|---|---|
| Male, n (%) | 1292 (59) | 1266 (59) | 26 (65) | .410 |
| Female, n (%) | 911 (41) | 897 (41) | 14 (35) | |
| Age, median (range), y | 47 (18-60) | 47 (18-60) | 51 (19-60) | .370 |
| LDH > upper normal value, n (%) | 1102 (50) | 1070 (49) | 32 (80) | <.001 |
| ECOG >1, n (%) | 193 (9) | 183 (8) | 10 (25) | .002 |
| Stage III/IV, n (%) | 1031 (47) | 1003 (46) | 28 (70) | .003 |
| aaIPI, n (%) | ||||
| 0 | 652 (30) | 651 (30) | 1 (2) | <.001 |
| 1 | 924 (42) | 906 (42) | 18 (45) | |
| 2 | 479 (22) | 468 (22) | 11 (28) | |
| 3 | 148 (7) | 138 (6) | 10 (25) | |
| Extralymphatic involvement, n (%) | 1210 (55) | 1183 (55) | 27 (68) | .107 |
| Extralymphatic involvement >1, n (%) | 509 (23) | 496 (23) | 13 (32) | .155 |
| Bulky disease† (>10 cm), n (%) | 462 (21) | 448 (21) | 14 (35) | .029 |
| B symptoms, n (%)† | 654 (30) | 635 (29) | 19 (49) | .009 |
| BM involvement, n (%) | 142 (6) | 135 (6) | 7 (18) | .012 |
| Kidney involvement at staging, n (%) | 56 (3) | 53 (2) | 3 (8) | .079 |
| Adrenal gland involvement at staging, n (%) | 33 (1) | 31 (1) | 2 (5) | .119 |
| Kidney and/or adrenal gland involvement at staging, n (%) | 81 (4) | 77 (4) | 4 (10) | .057 |
| CNS-IPI, n (%) | ||||
| 0 | 640 (29) | 639 (30) | 1 (2) | <.001 |
| 1 | 759 (34) | 744 (34) | 15 (38) | |
| 2 | 414 (19) | 403 (19) | 11 (28) | |
| 3 | 251 (11) | 245 (11) | 6 (15) | |
| 4 | 119 (5) | 116 (5) | 3 (8) | |
| 5 | 20 (1) | 16 (1) | 4 (10) | |
| CNS-IPI groups, n (%) | .002 | |||
| 0-1, low risk | 1399 (64) | 1383 (64) | 16 (40) | |
| 2-3, intermediate risk | 665 (30) | 648 (30) | 17 (42) | |
| 4-5, high risk | 139 (6) | 132 (6) | 7 (18) | |
| MTX prophylaxis (at least 1 course), n (%) | — | |||
| MTX IT† | 780 (38) | 766 (38) | 14 (40) | |
| HD MTX IV | 344 (16) | 342 (16) | 2 (5) | |
| CNS event, n (%) | — | — | ||
| At first progression/relapse (within the first 3 y) | 33 (1.5) (27) | 33 (82) (27) | ||
| After first progression/relapse (within the first 3 y) | 7 (0.3) (4) | 7 (18) (4) |